Cargando…

Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge

Modified Vaccinia Ankara (MVA) was recently approved as a smallpox vaccine. Variola is transmitted by respiratory droplets and MVA immunization by skin scarification (s.s.) protected mice far more effectively against lethal respiratory challenge with vaccinia virus (VACV) than any other route of del...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Youdong, Liu, Luzheng, Tian, Tian, Zhao, Jingxia, Park, Chang Ook, Lofftus, Serena Y., Stingley, Claire A., Yan, Yu, Mei, Shenglin, Liu, Xing, Kupper, Thomas S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782760/ https://www.ncbi.nlm.nih.gov/pubmed/33398010 http://dx.doi.org/10.1038/s41541-020-00265-5

Ejemplares similares

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production
por: Gränicher, Gwendal, et al.
Publicado: (2020)

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
por: Tenesaca, Shirley, et al.
Publicado: (2021)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques
por: Florek, Kelsey R., et al.
Publicado: (2017)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

Dendritic Cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo
por: Liu, Luzheng, et al.
Publicado: (2008)

Design and Engineering of Deimmunized Vaccinia Viral Vectors
por: Song, Kevin, et al.
Publicado: (2020)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

The production of recombinant platelet‐derived growth factor D using the second generation modified vaccinia Ankara viral system
por: Najy, Abdo J., et al.
Publicado: (2022)

Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model
por: Nörder, Miriam, et al.
Publicado: (2010)

Disruption of TNFα/TNFR1 function in resident skin cells impairs host immune response against cutaneous vaccinia virus infection
por: Tian, Tian, et al.
Publicado: (2012)

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies
por: Garber, David A., et al.
Publicado: (2009)

The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV
por: Chinnakannan, Senthil K., et al.
Publicado: (2020)

Vectors Based on Modified Vaccinia Ankara Expressing Influenza H5N1 Hemagglutinin Induce Substantial Cross-Clade Protective Immunity
por: Hessel, Annett, et al.
Publicado: (2011)

A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection
por: Malherbe, Delphine C., et al.
Publicado: (2022)

Physical disruption of skin during poxvirus immunization is critical for the generation of highly protective T cell-mediated immunity
por: Liu, Luzheng, et al.
Publicado: (2010)

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins
por: Di Mario, Giuseppina, et al.
Publicado: (2017)

A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs
por: Routhu, Nanda Kishore, et al.
Publicado: (2021)

Early viral protein synthesis is necessary for NF-κB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells
por: Martin, Stefani, et al.
Publicado: (2009)

Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
por: Altenburg, Arwen F., et al.
Publicado: (2018)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
por: Churchyard, Gavin, et al.
Publicado: (2016)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine
por: Rosenbaum, Pierre, et al.
Publicado: (2018)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Yang, Ning, et al.
Publicado: (2022)

OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs
por: Yang, Ning, et al.
Publicado: (2023)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
por: Julander, Justin G., et al.
Publicado: (2018)

Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine
por: Lopera-Madrid, Jaime, et al.
Publicado: (2017)

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
por: Hinterberger, Maria, et al.
Publicado: (2021)

Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice
por: Pursell, Taylor, et al.
Publicado: (2022)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara
por: Jordan, Ingo, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_pj6i7pn2jctjnrlcdalq8hf18r